Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

PURPOSE: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. PATIENTS AND METHODS: This randomized phase II, two-part, multicenter trial included newly diagnosed women with HER2-positive invasive breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Bundred, Nigel, Porta, Nuria, Brunt, Adrian Murray, Cramer, Angela, Hanby, Andrew, Shaaban, Abeer M., Rakha, Emad A., Armstrong, Anne, Cutress, Ramsey I., Dodwell, David, Emson, Marie A., Evans, Abigail, Hartup, Sue M., Horgan, Kieran, Miller, Sarah E., McIntosh, Stuart A., Morden, James P., Naik, Jay, Narayanan, Sankaran, Ooi, Jane, Skene, Anthony I., Cameron, David A., Bliss, Judith M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610457/
https://www.ncbi.nlm.nih.gov/pubmed/35165099
http://dx.doi.org/10.1158/1078-0432.CCR-21-3177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610457/
https://www.ncbi.nlm.nih.gov/pubmed/35165099
http://dx.doi.org/10.1158/1078-0432.CCR-21-3177

Ejemplares similares